Elsevier announces standards-ready clinical decision support enhancements in Gold Standard Drug Database to enable interoperability and transparency in healthcare applications

Elsevier announced new clinical decision support (CDS) enhancements in its Gold Standard Drug Database (GSDD) that enable customers to use industry-standard identifiers across core medication safety checks and provide transparent responses when no alert is triggered. The updates aim to help healthcare technology companies and pharmacy organizations integrate CDS faster, reduce manual exception queues, and operate confidently in multi‑vendor ecosystems.

GSDD now accepts RxNorm (RxCUIs) ICD‑10-CM, ICD-10-PCS and SNOMED CT as inputs for drug interaction, duplicate therapy and drug–disease safety checks, including contraindications and precautions. New input validation delivers explicit “reason responses” when no alert is produced, giving product and engineering teams clear, actionable insight into CDS behavior.

Elsevier is also enhancing Drug-Allergy safety checking, made available in March 2026, with support for RxCUI and SNOMED CT allergen inputs. A new allergy catalogue will be introduced to support clinician, patient, and consumer documentation, RxNorm and SNOMED CT drug substances, brands, drug classes, dietary and environmental allergens.

Rhett Alden, Chief Technology Officer at Elsevier said “These standards-ready capabilities reflect our commitment to helping customers meet interoperability requirements while improving operational efficiency. RxNorm, ICD-10, and SNOMED CT are cornerstone clinical terminologies that make interoperability possible by ensuring different systems mean the same thing when they exchange data. By utilizing these industry standard identifiers and providing transparent responses, we’re supporting safer, faster workflows without requiring our valued customers to rearchitect their systems. Transparency matters in clinical decision support – clear responses reduce unnecessary exception reviews and accelerate troubleshooting. Combined with standards-based inputs, customers can implement CDS more quickly and trust the results they see.”

The enhancements reinforce Elsevier’s clinical depth and ongoing content maintenance, aligning with the company’s broader focus on delivering safety, efficiency, and scalability across the health information ecosystem.

About Gold Standard Drug Database

Elsevier’s Gold Standard Drug Database (GSDD) provides normalized, clinically curated medication product and semantic data to help organizations standardize drug information and support medication management, clinical decision support, and interoperability across healthcare workflows. Maintained by clinical pharmacists and subject‑matter experts, GSDD integrates via flexible data feeds and APIs and is used by health systems, payers, pharmacies, and health‑technology companies.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업이다. 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔다. 전 세계 170개국에서 학계 및 기업 연구 커뮤니티와 의사, 간호사, 미래 의료 전문가, 교육자들이 수행하는 중요한 업무를 지원한다. 세계 최고 수준의 근거 기반 과학·의학 콘텐츠와 정밀 AI, 전문가 평가를 토대로 구축한 연구 및 임상 등급 솔루션을 제공하여 의미 있는 변화를 만들어가는 사람들에게 더 나은 성과를 거둘 수 있도록 돕는다. 또한 포용성과 지속가능성 증진에 앞장서며 엘스비어가 지원하는 커뮤니티와 협력한다. 엘스비어 재단(The Elsevier Foundationopens in new tab/window)은 전 세계의 연구 및 보건 파트너십을 지원한다.

엘스비어는 전문가 및 기업 고객에게 정보 기반 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원이다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아볼 수 있다.